| GTO ID | GTC2112 |
| Trial ID | NCT03946800 |
| Disease | Cancer |
| Altered gene | IL-12 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA |
| Treatment | MEDI1191 |
| Co-treatment | Durvalumab |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors |
| Year | 2019 |
| Country | United States|Spain |
| Company sponsor | MedImmune LLC |
| Other ID(s) | D8510C00001|2020-005784-31 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||